Big apple-based biotech’s new gene therapy subsidiary inks UNC licensing deals – Triangle Business Journal
Triangle Business Journal |
Big apple-based biotech's new gene therapy subsidiary inks UNC licensing deals
Triangle Business Journal Fortress' new subsidiary – New York-based Tamid Bio – will focus on the development of adeno-associated virus (AAV) gene therapies for the treatment of rare orphan diseases, according to the company. AAV's use in gene therapy is particularly popular … |
